
    
      This study is to see the regression rate of Cervical Intraepithelial Neoplasia (CIN3) and to
      see the inducement of Cytotoxic T Lymphocyte.

      The First treatment group will be administered with BLS-ILB-E710c 500mg for 8 weeks followed
      by 1 week observation The Second treatment group will be administered with BLS-ILB-E710c
      1000mg for 8 weeks followed by 1 week observation The Third treatment group will be
      administered with BLS-ILB-E710c 1500mg for 8 weeks followed by 1 week observation The fourth
      treatment group will be administered with BLS-ILB-E710c Optimum dose for 8 weeks followed by
      8 weeks observation
    
  